Discovery of antimicrobial compounds targeting bacterial type FAD synthetases

References

• Spellberg B, Powers JH, Brass EP, et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279–86.
   PubMed Web of Science ®Google Scholar
• Conly J, Johnston B. Where are all the new antibiotics? The new antibiotic paradox. Can J Infect Dis Med Microbiol 2005;16:159–60.
   PubMedGoogle Scholar
• Walsh CT, Wencewicz TA. Prospects for new antibiotics: a molecule-centered perspective. J Antibiot (Tokyo) 2014;67:7–22.
   PubMed Web of Science ®Google Scholar
• WHO. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. WHO/EMP/IAU/2017.11 ed. World Health Organization: Geneva; 2017.
   Google Scholar
• Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature 2016;529:336–43.
   PubMed Web of Science ®Google Scholar
• Lienhart WD, Gudipati V, Macheroux P. The human flavoproteome. Arch Biochem Biophys 2013;535:150–62.
   PubMed Web of Science ®Google Scholar
• Gudipati V, Koch K, Lienhart WD, Macheroux P. The flavoproteome of the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 2014;1844:535–44.
   PubMed Web of Science ®Google Scholar
• Barile M, Giancaspero TA, Leone P, et al. Riboflavin transport and metabolism in humans. J Inherit Metab Dis 2016;39:545–57.
   PubMed Web of Science ®Google Scholar
• Gross E, Kastner DB, Kaiser CA, Fass D. Structure of Ero1p, source of disulfide bonds for oxidative protein folding in the cell. Cell 2004;117:601–10.
   PubMed Web of Science ®Google Scholar
• Parsons HG, Dias VC. Intramitochondrial fatty acid metabolism: riboflavin deficiency and energy production. Biochem Cell Biol 1991;69:490–7.
   PubMed Web of Science ®Google Scholar
• Myllykallio H, Lipowski G, Leduc D, et al. An alternative flavin-dependent mechanism for thymidylate synthesis. Science 2002;297:105–7.
   PubMed Web of Science ®Google Scholar
• Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999;397:441–6.
   PubMed Web of Science ®Google Scholar
• Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003;48:77–84.
   PubMed Web of Science ®Google Scholar
• Griffin JE, Gawronski JD, Dejesus MA, et al. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 2011;7:e1002251.
   PubMed Web of Science ®Google Scholar
• Serrano A, Ferreira P, Martínez-Júlvez M, Medina M. The prokaryotic FAD synthetase family: a potential drug target. Curr Pharm Des 2013;19:2637–48.
   PubMed Web of Science ®Google Scholar
• Barile M, Passarella S, Bertoldi A, Quagliariello E. Flavin adenine dinucleotide synthesis in isolated rat liver mitochondria caused by imported flavin mononucleotide. Arch Biochem Biophys 1993;305:442–7.
   PubMed Web of Science ®Google Scholar
• Serrano A, Frago S, Velázquez-Campoy A, Medina M. Role of key residues at the flavin mononucleotide (FMN):adenylyltransferase catalytic site of the bifunctional riboflavin kinase/flavin adenine dinucleotide (FAD) synthetase from Corynebacterium ammoniagenes. Int J Mol Sci 2012;13:14492–517.
   PubMed Web of Science ®Google Scholar
• Efimov I, Kuusk V, Zhang X, McIntire WS. Proposed steady-state kinetic mechanism for Corynebacterium ammoniagenes FAD synthetase produced by Escherichia coli. Biochemistry 1998;37:9716–23.
   PubMed Web of Science ®Google Scholar
• Mack M, van Loon AP, Hohmann HP. Regulation of riboflavin biosynthesis in Bacillus subtilis is affected by the activity of the flavokinase/flavin adenine dinucleotide synthetase encoded by ribC. J Bacteriol 1998;180:950–5.
   PubMed Web of Science ®Google Scholar
• Herguedas B, Martínez-Júlvez M, Frago S, et al. Crystallization and preliminary X-ray diffraction studies of FAD synthetase from Corynebacterium ammoniagenes. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009;65:1285–8.
   PubMedGoogle Scholar
• Wang W, Kim R, Yokota H, Kim SH. Crystal structure of flavin binding to FAD synthetase of Thermotoga maritima. Proteins 2005;58:246–8.
   PubMed Web of Science ®Google Scholar
• Wang W, Kim R, Jancarik J, et al. Crystal structure of a flavin-binding protein from Thermotoga maritima. Proteins 2003;52:633–5.
   PubMed Web of Science ®Google Scholar
• Sebastián M, Lira-Navarrete E, Serrano A, et al. The FAD synthetase from the human pathogen Streptococcus pneumoniae: a bifunctional enzyme exhibiting activity-dependent redox requirements. Sci Rep 2017;7:7609.
   PubMed Web of Science ®Google Scholar
• Herguedas B, Martinez-Julvez M, Frago S, et al. Oligomeric state in the crystal structure of modular FAD synthetase provides insights into its sequential catalysis in prokaryotes. J Mol Biol 2010;400:218–30.
   PubMed Web of Science ®Google Scholar
• Giancaspero TA, Galluccio M, Miccolis A, et al. Human FAD synthase is a bi-functional enzyme with a FAD hydrolase activity in the molybdopterin binding domain. Biochem Biophys Res Commun 2015;465:443–9.
   PubMed Web of Science ®Google Scholar
• Serrano A, Sebastian M, Arilla-Luna S, et al. Quaternary organization in a bifunctional prokaryotic FAD synthetase: involvement of an arginine at its adenylyltransferase module on the riboflavin kinase activity. Biochim Biophys Acta 2015;1854:897–906.
   Web of Science ®Google Scholar
• Serrano A, Frago S, Herguedas B, et al. Key residues at the riboflavin kinase catalytic site of the bifunctional riboflavin kinase/FMN adenylyltransferase from Corynebacterium ammoniagenes. Cell Biochem Biophys 2013;65:57–68.
   PubMed Web of Science ®Google Scholar
• Herguedas B, Lans I, Sebastián M, et al. Structural insights into the synthesis of FMN in prokaryotic organisms. Acta Crystallogr D Biol Crystallogr 2015;71:2526–42.
   PubMedGoogle Scholar
• Frago S, Velázquez-Campoy A, Medina M. The puzzle of ligand binding to Corynebacterium ammoniagenes FAD synthetase. J Biol Chem 2009;284:6610–19.
   PubMed Web of Science ®Google Scholar
• Frago S, Martínez-Júlvez M, Serrano A, Medina M. Structural analysis of FAD synthetase from Corynebacterium ammoniagenes. BMC Microbiol 2008;8:160.
   PubMed Web of Science ®Google Scholar
• Lagorce D, Oliveira N, Miteva MA, Villoutreix BO. Pan-assay interference compounds (PAINS) that may not be too painful for chemical biology projects. Drug Discov Today 2017;22:1131–3.
   PubMed Web of Science ®Google Scholar
• Cosconati S, Forli S, Perryman AL, et al. Virtual screening with AutoDock: theory and practice. Expert Opin Drug Discov 2010;5:597–607.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• Forli S, Olson AJ. A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking. J Med Chem 2012;55:623–38.
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09. Wallingford, CT: Gaussian Inc.; 2016.
   Google Scholar
• Palomino JC, Martin A, Camacho M, et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:2720–2.
   PubMed Web of Science ®Google Scholar
• Olsson TS, Williams MA, Pitt WR, Ladbury JE. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. J Mol Biol 2008;384:1002–17.
   PubMed Web of Science ®Google Scholar
• Deu E, Yang Z, Wang F, et al. Use of activity-based probes to develop high throughput screening assays that can be performed in complex cell extracts. PLoS One 2010;5:e11985.
   PubMed Web of Science ®Google Scholar
• Zhang G. Protease assays. Available from: http://www.ncbi.nlm.nih.gov/books/NBK92006/
   Google Scholar
• Saxena T, Loomis KH, Pai SB, et al. Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury. ACS Nano 2015;9:1492–505.
   PubMed Web of Science ®Google Scholar
• Normand A, Rivière E, Renodon-Cornière A. Identification and characterization of human Rad51 inhibitors by screening of an existing drug library. Biochem Pharmacol 2014;91:293–300.
   PubMed Web of Science ®Google Scholar
• Risse E, Nicoll AJ, Taylor WA, et al. Identification of a compound that disrupts binding of Amyloid-β to the prion protein using a novel fluorescence-based assay. J Biol Chem 2015;290:17020–8.
   PubMed Web of Science ®Google Scholar
• He Z, Yan L, Yong Z, et al. Chicago sky blue 6B, a vesicular glutamate transporters inhibitor, attenuates methamphetamine-induced hyperactivity and behavioral sensitization in mice. Behav Brain Res 2013;239:172–6.
   PubMed Web of Science ®Google Scholar
• Klebe G. Applying thermodynamic profiling in lead finding and optimization. Nat Rev Drug Discov 2015;14:95–110.
   PubMed Web of Science ®Google Scholar
• Soufir JC. Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France. Basic Clin Androl 2017;27:3.
   PubMed Web of Science ®Google Scholar
• Ferdek PE, Jakubowska MA, Nicolaou P, et al. BH3 mimetic-elicited Ca(2+) signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca(2+)-like peptides. Cell Death Dis 2017;8:e2640.
   PubMed Web of Science ®Google Scholar
• Xiong J, Li J, Yang Q, et al. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res 2017;19:27
   PubMed Web of Science ®Google Scholar
• Polsky B, Segal SJ, Baron PA, et al. Inactivation of human immunodeficiency virus in vitro by gossypol. Contraception 1989;39:579–87.
   PubMed Web of Science ®Google Scholar
• Newby NC, Leslie KE, Dingwell HD, et al. The effects of periparturient administration of flunixin meglumine on the health and production of dairy cattle. J Dairy Sci 2017;100:582–7.
   PubMed Web of Science ®Google Scholar
• Kleinhenz MD, Van Engen NK, Gorden PJ, et al. The pharmacokinetics of transdermal flunixin meglumine in Holstein calves. J Vet Pharmacol Ther 2016;39:612–15.
   PubMed Web of Science ®Google Scholar
• Burkett BN, Thomason JM, Hurdle HM, et al. Effects of firocoxib, flunixin meglumine, and phenylbutazone on platelet function and thromboxane synthesis in healthy horses. Vet Surg 2016;45:1087–94.
   PubMed Web of Science ®Google Scholar
• Torres A, Blasi F, Peetermans WE, et al. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis 2014;33:1065–79.
   PubMed Web of Science ®Google Scholar
• WHO. Global Tuberculosis Report. Geneva: WHO; 2016.
   Google Scholar
• Seidel M, Alderwick LJ, Sahm H, et al. Topology and mutational analysis of the single Emb arabinofuranosyltransferase of Corynebacterium glutamicum as a model of Emb proteins of Mycobacterium tuberculosis. Glycobiology 2007;17:210–19.
   PubMed Web of Science ®Google Scholar
• Chan CY, Prudom C, Raines SM, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 subunit a (Vph1p). J Biol Chem 2012;287:10236–50.
   PubMed Web of Science ®Google Scholar
• Zhu X, Gao JJ, Landao-Bassonga E, et al. Thonzonium bromide inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Biochem Pharmacol 2016;104:118–30.
   PubMed Web of Science ®Google Scholar
• Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139–51.
   PubMed Web of Science ®Google Scholar
• Shin YH, Min JJ, Lee JH, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts. Heart Vessels 2017;32:618–27.
   Web of Science ®Google Scholar
• Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008;103:1383–9.
   PubMed Web of Science ®Google Scholar
• Dallegri F, Bertolotto M, Ottonello L. A review of the emerging profile of the anti-inflammatory drug oxaprozin. Expert Opin Pharmacother 2005;6:777–85.
   PubMed Web of Science ®Google Scholar
• Kara IM, Polat S, Inci MF, et al. Analgesic and anti-inflammatory effects of oxaprozin and naproxen sodium after removal of impacted lower third molars: a randomized, double-blind, placebo-controlled crossover study. J Oral Maxillofac Surg 2010;68:1018–24.
   PubMed Web of Science ®Google Scholar
• Montecucco F, Bertolotto M, Ottonello L, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol 2009;2009:478785.
   PubMedGoogle Scholar
• Grill S, Busenbender S, Pfeiffer M, et al. The bifunctional flavokinase/flavin adenine dinucleotide synthetase from Streptomyces davawensis produces inactive flavin cofactors and is not involved in resistance to the antibiotic roseoflavin. J Bacteriol 2008;190:1546–53.
   PubMed Web of Science ®Google Scholar
• Matern A, Pedrolli D, Groszhennig S, et al. Uptake and metabolism of antibiotics roseoflavin and 8-demethyl-8-aminoriboflavin in riboflavin-auxotrophic listeria monocytogenes. J Bacteriol 2016;198:3233–43.
   PubMed Web of Science ®Google Scholar
• Marcuello C, Arilla-Luna S, Medina M, Lostao A. Detection of a quaternary organization into dimer of trimers of Corynebacterium ammoniagenes FAD synthetase at the single-molecule level and at the in cell level. Biochim Biophys Acta 2013;1834:665–76.
   PubMed Web of Science ®Google Scholar
• Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013;12:371–87.
   PubMed Web of Science ®Google Scholar
• Stermitz FR, Lorenz P, Tawara JN, et al. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000;97:1433–7.
   PubMed Web of Science ®Google Scholar
• Rodrigues L, Parish T, Balganesh M, Ainsa JA. Antituberculosis drugs: reducing efflux = increasing activity. Drug Discov Today 2017;22:592–99.
   PubMed Web of Science ®Google Scholar
• Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 2010;9:23–7.
   PubMed Web of Science ®Google Scholar
• Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking Arabinan synthesis. Science 2009;324:801–4.
   PubMed Web of Science ®Google Scholar